<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2009234229
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Welireg
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        BELZUTIFAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        90
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        68062.50
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MSD INTERNATIONAL GMBH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MSD INTERNATIONAL GMBH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MERCK SHARP & DOHME LIMITED
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Welireg contains the active ingredient belzutifan.</p><p>Welireg is a medicine used to treat adults with von Hippel‑Lindau (VHL) disease who need treatment for a type of kidney cancer called renal cell carcinoma (RCC), tumours in the brain and spinal cord called central nervous system hemangioblastomas, or a type of pancreatic cancer called pancreatic neuroendocrine tumours, and for whom surgery or other local procedures are unsuitable or undesirable. &nbsp;</p><p>How belzutifan works</p><p>Welireg is a hypoxia-inducible factor 2 alpha (HIF-2&alpha;) inhibitor which may slow or stop the growth of tumors in patients with VHL disease.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Welireg if: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are allergic to belzutifan or any of the other ingredients of this medicine (listed in section 6). Talk to your doctor if you are not sure.</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor or pharmacist before taking Welireg if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have breathing problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have heart problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have low levels of red blood cells (anaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are pregnant or plan to be pregnant</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Welireg may affect fertility, which may affect your ability to have children. Talk to your doctor if this is a concern for you.</p><p>&nbsp;</p><p>If any of the above apply to you (or you are not sure) talk to your doctor before taking this medicine.</p><p>&nbsp;</p><p>Welireg may decrease your red blood cell level. Common symptoms include shortness of breath, fatigue, dizziness, and pale skin. Although symptoms vary from person to person, low blood cell counts that can be serious may require a blood transfusion if your blood cell counts drop too low. Contact your doctor immediately if you develop any of the following symptoms: tiredness, feeling cold, chest pain, or fast heartbeat.</p><p>&nbsp;</p><p>Welireg may also decrease the oxygen level in your blood. Common symptoms include shortness of breath, increased heart rate, rapid breathing, and feeling anxious or restless. Although symptoms vary from person to person, low oxygen levels in your body that can be serious may require you to stop treatment with Welireg, receive oxygen therapy or be hospitalised. Contact your doctor immediately if you develop any of the following symptoms: bluish discoloration of the skin around your mouth, inability to speak in full sentences without catching your breath, unusual tiredness, and confusion. In light of this risk, you should stop smoking while taking Welireg.</p><p>Your doctor will regularly measure your oxygen level and do blood tests to check your red blood cell level during your treatment with Welireg.</p><p><strong>Children and adolescents</strong></p><p><u>Do not give this medicine to children and adolescents below the age of 18 years.</u></p><p>&nbsp;</p><p><strong>Other medicines and Welireg</strong></p><p>Tell your doctor or pharmacist about all the medicines you take. This is because Welireg can affect the way some other medicines work. Also, some other medicines can affect the way Welireg works.</p><p>&nbsp;</p><p>Some medicines may increase the risk of side effects with Welireg, for example:</p><p>&sect;&nbsp; imatinib (used to treat cancer)</p><p>&sect;&nbsp; fluconazole (used to treat fungal infections)</p><p>&sect;&nbsp; fluoxetine, fluvoxamine (used to treat depressive disorders)</p><p>&nbsp;</p><p>Welireg may affect the way other medicines work, for example:</p><p>&sect;&nbsp; hormonal contraceptives such as desogestrel, ethinylestradiol and levonorgestrel&nbsp;</p><p>&sect;&nbsp; alfentanil (used as a supplement before or during anesthesia)</p><p>&sect;&nbsp; lurasidone (used to treat schizophrenia or bipolar depression)</p><p>&sect;&nbsp; sirolimus, tacrolimus (used as prophylaxis of organ rejection in transplants)</p><p>&nbsp;</p><p>Your doctor will decide if the dose needs to be changed.</p><p>&nbsp;</p><p><strong>Pregnancy information for women and men</strong></p><p>If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist before taking this medicine.</p><p>Your doctor will carry out a pregnancy test before you start taking the medicine.</p><p>Welireg may harm your unborn baby and cause a miscarriage. This means:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should not become pregnant while taking Welireg</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should not take Welireg if you are pregnant.</p><p>&nbsp;</p><p><strong>Contraception in women and men</strong></p><p><em>Women</em></p><p>If you are a woman who could get pregnant:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Birth control methods that contain hormones (such as birth control pills, injections, or transdermal system patches) may not work as well during treatment with Welireg. You should use an effective form of non-hormonal birth control (contraception) or have your male partner use a condom during treatment with Welireg and for 1 week after your last dose.</p><p>&nbsp;</p><p>Talk to your doctor or pharmacists about birth control methods that may be right for you during this time.</p><p>If you become pregnant while using Welireg, talk to your doctor straight away.</p><p><em>Men</em></p><p>Welireg may be passed on to an unborn baby and harm it. If you are a man whose female partner could get pregnant:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You and your partner should use effective contraception while taking Welireg.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Also do this for at least 1 week after your last dose of Welireg.</p><p>If your partner becomes pregnant while you are using Welireg, talk to your doctor straight away.</p><p>If you are a man whose female partner is pregnant:</p><p>Use a barrier method of contraception during treatment with belzutifan and 1 week after last dose.</p><p>&nbsp;</p><p><strong>Breast-feeding</strong></p><p>Do not breast‑feed during treatment with Welireg.&nbsp; It is not known if Welireg passes into your breast milk; it may harm your baby.</p><p>You should not breast feed for at least one week after your last dose of Welireg.</p><p>&nbsp;</p><p><strong>Fertility</strong></p><p>Welireg may impair fertility. If you are planning to have a baby with your partner - talk to your doctor about family planning before taking Welireg.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>You may feel dizzy or tired after taking Welireg. If this happens, do not drive or use tools or machines until you no longer feel dizzy or tired.</p><p>&nbsp;</p><p><strong>Welireg contains sodium</strong></p><p>This medicine contains less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say essentially &lsquo;sodium-free&rsquo;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p><strong>How much to take</strong></p><p>The recommended dose of Welireg is 120 mg (three 40 mg tablets):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take your prescribed dose once a day, at the same time each day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor may change your dose if needed.</p><p>&nbsp;</p><p><strong>How to take</strong></p><p>Swallow the tablet whole - do not break, crush, or chew the tablet.</p><p>You can take Welireg with or without food.</p><p>&nbsp;</p><p><strong>If you take more Welireg than you should</strong></p><p>If you take too many tablets contact a doctor or hospital for advice. Medical treatment may be necessary. &nbsp;&nbsp;</p><p>&nbsp;</p><p><strong>If you forget to take Welireg</strong></p><p>If you miss a dose of Welireg, take the missed dose as soon as possible on the same day. Take your regular dose of Welireg the next day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you vomit after taking Welireg, do not take another Welireg tablet. Take your regular dose of Welireg the next day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take a double dose to make up for forgotten or vomited dose.</p><p>&nbsp;</p><p>If you are not sure how to take Welireg, call your doctor or pharmacist</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Possible</strong><strong> side effects are:</strong></p><p><strong>Very Common:</strong> may affect more than 1 in 10 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low red blood cells (anaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling tired</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling dizzy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have difficulty breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea)</p><p>&nbsp;</p><p>Tell your doctor if you notice any of the side effects listed above.</p><p>&nbsp;</p><p><strong>Common:</strong> may affect up to 1 in 10 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormally low oxygen levels in the blood</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via The National Pharmacovigilance Centre (NPC) , SFDA. .&nbsp;&nbsp; By reporting side effects you can help provide more information on the safety of this medicine</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Store below 30&deg;C.</p><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the bottle and the carton after &ldquo;EXP&rdquo;.</p><p>Do not use this medicine if the packaging is damaged or shows signs of tampering.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Welireg contains </strong></p><p>The active substance is belzutifan. Each film-coated tablet contains 40 mg of belzutifan.</p><p>The other ingredients are croscarmellose sodium, hypromellose acetate succinate, magnesium stearate, mannitol, cellulose microcrystalline, and colloidal anhydrous silica. The film-coat contains indigo carmine aluminium lake, macrogol, polyvinyl alcohol, talc, titanium dioxide.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
Welireg is a blue, round film-coated tablet, debossed with 177 on one side and plain on the other side.

Welireg is available in HDPE bottles with 90 film-coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder </strong></p><p>Merck Sharp &amp; Dohme (UK) Limited, 120 Moorgate, London EC2M 6UR, UK</p><p><strong>&nbsp;</strong></p><p><strong>Manufacturer</strong></p><p>MSD International GmbH T/A MSD</p><p>Ireland (Ballydine)</p><p>Kilsheelan, Clonmel, Co. Tipperary,</p><p>Ireland</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
	This leaflet was last revised in Dec 2023
	Revision No. (1)
	
	
To report any side effect(s):
•	Saudi Arabia: 
The National Pharmacovigilance Centre (NPC):
Fax: +966-11-205-7662
SFDA Call Center: 19999
E-mail: npc.drug@sfda.gov.sa
Website: https://ade.sfda.gov.sa

•	Other GCC States: 
Please contact the relevant competent authority.

This is a Medicament
	Medicament  is  a  product  which  affects  your  health  and  its  consumption  contrary  to instructions is dangerous for you.
	Follow strictly the doctor’s prescription, the method of use and the instructions  of the pharmacist who sold the medicament.
	The doctor and the pharmacist are the experts in medicines, their benefits and risks.
	Do not by yourself interrupt the period of treatment prescribed for you.
	Do not repeat the same prescription without consulting your doctor.
	Keep all medicaments out of reach of children.

Council of Arab Health Ministers 
Union of Arab Pharmacists

This patient information leaflet is approved by the Saudi Food and Drug Authority
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي ويليرق &nbsp;على المادة الفعالة بيلزوتيفان. &nbsp;</p><p dir="RTL">ويليرق &nbsp;هو دواء يستخدم لعلاج البالغين المصابين بمرض فون هيبل لينداو (VHL) الذين يحتاجون إلى علاج لنوع من سرطان الكلى يسمى سرطان الخلايا الكلوية (RCC)، أو أورام الدماغ والحبل الشوكي التي تسمى الأورام الأرومية الوعائية في الجهاز العصبي المركزي ، أو نوع من سرطان البنكرياس يسمى أورام البنكرياس العصبية الصماوية ، وكذلك المرضى ممن لا تعد الجراحة أو الإجراءات الموضعية &nbsp;مناسبة أو غير مرغوب فيها لهم.</p><p dir="RTL">آلية عمل بيلزوتيفان</p><p dir="RTL">ويليرق &nbsp;هو مثبط للعامل 2 ألفا المُحفّز لنقص الأكسجين (2&alpha;-HIF) والذي قد يبطئ أو يوقف نمو الأورام في المرضى الذين يعانون من مرض VHL.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول ويليرق &nbsp;إذا : </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك حساسية تجاه بيلزوتيفان &nbsp;أو أي من المكونات الأخرى لهذا الدواء (المدرجة في الفقرة 6) . &nbsp;تحدث إلى طبيبك إذا لم تكن متأكدا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التحذيرات والاحتياطات </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحدث إلى طبيبك أو الصيدلي قبل تناول ويليرق &nbsp;إذا :</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك مشاكل في التنفس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك مشاكل في القلب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك مستويات منخفضة من خلايا الدم الحمراء (فقر الدم)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنتِ حاملًا أو تخططين للحمل</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يؤثر ويليرق &nbsp;على الخصوبة ، مما قد يؤثر على قدرتك على إنجاب الأطفال. تحدث إلى طبيبك إذا كان هذا يُشكل قلقًا لك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان أي مما سبق ينطبق عليك (أو لست متأكدًا) تحدث إلى طبيبك قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يقلل ويليرق &nbsp;من مستوى خلايا الدم الحمراء لديك. تشمل الأعراض الشائعة لهذا العرَض ضيق التنفس والتعب والدوخة وشحوب الجلد.</p><p dir="RTL">على الرغم من أن الأعراض تختلف من شخص لآخر، إلا أن انخفاض عدد خلايا الدم الذي يمكن أن يكون خطيرا قد يتطلب نقل دم إذا انخفض عدد خلايا الدم لديك بشكل كبير. اتصل بطبيبك على الفور إذا ظهرت عليك أي من الأعراض التالية: التعب أو الشعور بالبرد أو ألم في الصدر أو تسارع ضربات القلب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يقلل ويليرق &nbsp;أيضا من مستوى الأكسجين في الدم لديك. تشمل الأعراض الشائعة ضيق التنفس وزيادة معدل ضربات القلب والتنفس السريع والشعور بالقلق أو الاضطراب. على الرغم من أن الأعراض تختلف من شخص لآخر، إلا أن انخفاض مستويات الأكسجين في جسمك بشكل خطير قد يتطلب منك التوقف عن العلاج باستخدام ويليرق &nbsp;أو تلقي العلاج بالأكسجين أو دخول المستشفى. &nbsp;اتصل بطبيبك على الفور إذا ظهرت عليك أيّ من الأعراض التالية : ازرقاق لون الجلد حول فمك، وعدم القدرة على التحدث بجمل كاملة دون التقاط أنفاسك، والتعب غير العادي ، والارتباك.&nbsp; في ضوء هذا الخطر، يجب عليك التوقف عن التدخين أثناء تناول ويليرق .</p><p dir="RTL">سيقوم طبيبك بقياس مستوى الأكسجين بانتظام لديك وإجراء اختبارات الدم للتحقق من مستوى خلايا الدم الحمراء أثناء علاجك بويليرق .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL"><u>لا تعطِ هذا الدواء للأطفال والمراهقين دون سن 18 عامًا.</u></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أدوية أخرى و ويليرق &nbsp;</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي عن جميع الأدوية التي تتناولها. وذلك لأن ويليرق &nbsp;يمكن أن يؤثر على الطريقة التي تعمل بها بعض الأدوية الأخرى. كما يمكن أن تؤثر بعض الأدوية الأخرى على طريقة عمل ويليرق .</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تزيد بعض الأدوية من خطر حدوث الأعراض الجانبية مع ويليرق ، على سبيل المثال :</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيماتينيب (يستخدم لعلاج السرطان)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فلوكونازول (يستخدم لعلاج الالتهابات الفطرية)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فلوكسيتين، فلوفوكسامين (يستخدم لعلاج الاضطرابات الاكتئابية)</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يؤثر ويليرق &nbsp;على طريقة عمل الأدوية الأخرى، على سبيل المثال :</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وسائل منع الحمل الهرمونية مثل ديسوجيستريل وإيثينيل إستراديول وليفونورجيستريل</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألفنتانيل (يستخدم كأحد الأدوية المستخدمة قبل أو أثناء التخدير)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لوراسيدون (يستخدم لعلاج الفصام أو الاكتئاب ثنائي القطب)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيروليموس، تاكروليموس (يستخدم كوقاية من رفض الأعضاء في عمليات الزرع)</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيقرر طبيبك ما إذا كانت الجرعة لديك بحاجة إلى تغيير.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات للنساء والرجال عن الاستخدام أثناء الحمل</strong></p><p dir="RTL">إذا كنتِ حاملًا ، أو تعتقدين أنك قد تكونين حاملًا ، أو تخططين لإنجاب طفل ، فاطلبي من طبيبك أو الصيدلي المشورة قبل تناول هذا الدواء.</p><p dir="RTL">سيقوم طبيبك بإجراء اختبار الحمل لكِ قبل البدء في تناول الدواء.</p><p dir="RTL">قد يضر ويليرق &nbsp;بجنينك ويسبب الإجهاض ، وهذا يعني:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن تتجنبي حدوث الحمل أثناء تناول ويليرق</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم استخدام ويليرق &nbsp;إذا كنتِ حاملًا .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>وسائل منع الحمل لدى النساء والرجال</strong></p><p dir="RTL"><em>النساء</em></p><p dir="RTL">إذا كنت امرأة في سن الإنجاب:</p><p dir="RTL">قد لا تعمل طرق تحديد النسل التي تحتوي على هرمونات (مثل حبوب منع الحمل أو الحقن أو اللصقات الجلدية) بشكل جيد أثناء العلاج باستخدام ويليرق . يجب عليك استخدام شكل فعال من وسائل منع الحمل غير الهرمونية (وسائل منع الحمل) أو على شريكك أن يستخدم الواقي الذكري أثناء العلاج بويليرق &nbsp;ولمدة أسبوع واحد بعد تناول الجرعة الأخيرة.</p><p dir="RTL">تحدثي إلى طبيبك أو الصيدلي حول طرق تحديد النسل التي قد تكون مناسبة لك خلال هذا الوقت.</p><p dir="RTL">إذا أصبحتِ حاملًا أثناء استخدام ويليرق ، فتحدثي إلى طبيبك على الفور.</p><p dir="RTL"><em>الرجال</em></p><p dir="RTL">قد ينتقل ويليرق &nbsp;إلى الجنين ويؤذيه. إذا كنتَ رجلًا يمكن لشريكتك أن تحمل:</p><p dir="RTL">يجب عليك أنت وشريكتك استخدام وسائل منع الحمل الفعالة أثناء تناول ويليرق .</p><p dir="RTL">أيضا الاستمرار بذلك لمدة أسبوع واحد على الأقل بعد تناول الجرعة الأخيرة من ويليرق .</p><p dir="RTL">إذا أصبحت شريكتك حاملًا أثناء استخدامك ويليرق ، فتحدث إلى طبيبك على الفور.</p><p dir="RTL">إذا كنتَ رجلًا شريكته حاملا :</p><p dir="RTL">استخدم وسيلة حاجز لمنع الحمل أثناء العلاج ببيلزوتيفان ولمدة أسبوع واحد بعد تناول الجرعة الأخيرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الرضاعة الطبيعية</strong></p><p dir="RTL">تجنبي الرضاعة الطبيعية أثناء العلاج مع ويليرق .&nbsp; من غير المعروف ما إذا كان ويليرق &nbsp;يُفرز في حليب الثدي. قد يضر ذلك طفلك.</p><p dir="RTL">يجب عليك تجنب الرضاعة الطبيعية لمدة أسبوع واحد على الأقل بعد تناول آخر جرعة من ويليرق .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الخصوبة</strong></p><p dir="RTL">قد يضعف ويليرق &nbsp;الخصوبة. إذا كنت تخطط لإنجاب طفل - تحدث إلى طبيبك حول تنظيم الأسرة قبل تناول ويليرق .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد تشعر بالدوار أو التعب بعد تناول ويليرق . إذا حدث هذا، فلا تقُد السيارة أو تستخدم الأدوات أو الآلات حتى يزول الشعور بالدوار أو التعب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ويليرق </strong><strong>&nbsp;يحتوي على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مليمول صوديوم (23 مجم) في كل قرص مغلف بغشاء رقيق، أي &quot;خال من الصوديوم&quot; بشكل أساس</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول هذا الدواء دائمًا حسب إرشادات طبيبك أو الصيدلي تمامًا. استشر طبيبك أو الصيدلي إذا لم تكن متأكدا.</p><p dir="RTL"><strong>الجرعة</strong></p><p dir="RTL">الجرعة الموصى بها من ويليرق &nbsp;هي 120 ملغم (ثلاثة أقراص يحتوي كل منها على 40 مجم ملغم(</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول الجرعة الموصوفة مرة واحدة في اليوم ، في نفس الوقت كل يوم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يغير طبيبك الجرعة إذا لزم الأمر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>طريقة الاستخدام</strong></p><p dir="RTL">ابلع القرص بالكامل - لا تكسر أو تسحق أو تمضغ القرص.</p><p dir="RTL">يمكنك أن تتناول ويليرق &nbsp;مع أو بدون طعام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولت ويليرق &nbsp;أكثر مما ينبغي</strong></p><p dir="RTL">إذا تناولت الكثير من الأقراص، فاتصل بالطبيب أو المستشفى للحصول على المشورة. قد يكون العلاج الطبي ضروريا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت أن تتناول إحدى جرعات ويليرق &nbsp;&nbsp;</strong></p><p dir="RTL">إذا فاتتك جرعة من ويليرق ، تناول الجرعة الفائتة في أقرب وقت ممكن في نفس اليوم. تناول جرعتك المعتادة من ويليرق &nbsp;في اليوم التالي.</p><p dir="RTL">إذا تقيأت بعد تناول ويليرق ، فلا تتناول قرص ويليرق &nbsp;آخر. تناول جرعتك المعتادة من ويليرق &nbsp;في اليوم التالي.</p><p dir="RTL">لا تتناول جرعة مضاعفة للتعويض عن الجرعة المنسية أو المفقودة بالقيء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لم تكن متأكدًا من كيفية تناول ويليرق ، فاتصل بطبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع جميع الأدوية، يمكن أن يسبب هذا الدواء أعراضًا جانبية، على الرغم من أنها لا تحدث لدى جميع من يستخدمه.</p><p dir="RTL"><strong>الأعراض الجانبية المحتملة هي :</strong></p><p dir="RTL"><strong>شائعة جدا:</strong> قد تؤثر على أكثر من 1 من كل 10 أشخاص</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم الحمراء (فقر الدم)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتعب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدوار</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالمرض (الغثيان)</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك إذا لاحظت أيًّا من الأعراض الجانبية المذكورة أعلاه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة:</strong> قد تؤثر على ما يصل إلى 1 من كل 10 أشخاص</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات الأكسجين بشكل غير طبيعي في الدم</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا واجهت أي أعراض جانبية، تحدث إلى طبيبك أو الصيدلي. &nbsp;وهذا يشمل أي أعراض جانبية محتملة غير مدرجة في هذه النشرة. &nbsp;يمكنك أيضًا الإبلاغ عن الأعراض الجانبية مباشرة عبر &quot;المركز الوطني للتيقظ والسلامة الدوائية (NPC)، التابع للهيئة العامة للغذاء والدواء&quot; بالمملكة العربية السعودية. يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء من خلال الإبلاغ عن الأعراض الجانبية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">يُحفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على القارورة والكرتون بعد كلمة &quot;EXP&quot;.</p><p dir="RTL">لا تستخدم هذا الدواء إذا كانت العبوة تالفة أو تظهر عليها علامات العبث.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. وستساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات ويليرق &nbsp;&nbsp;</strong></p><p dir="RTL">المادة الفعالة هي بيلزوتيفان . يحتوي كل قرص مغلف بغشاء رقيق على 40 ملغم من بيلزوتيفان .</p><p dir="RTL">المكونات الأخرى هي الصوديوم كروسكارملوز، هيبروميلوز أسيتات ساكسينات، ستيرات المغنيسيوم، مانيتول، السليلوز دقيق التبلور، والسيليكا اللامائية الغروية.</p><p dir="RTL">مكونات الغشاء الرقيق عبارة عن اللون النيلي القرمزي، ماكروغول، كحول البولي فينيل، التالك، ثاني أكسيد التيتانيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشكل الصيدلاني لويليرق &nbsp;ووصفه وحجم عبوته </strong></p><p dir="RTL">ويليرق &nbsp;عبارة عن قرص أزرق مستدير مغطى بغشاء رقيق، منقوش على أحد جانبيه العدد177 والجانب الآخر خالٍ من الرموز.</p><p dir="RTL">يتوفر ويليرق &nbsp;في قوارير مصنوعة من (البوليإثيلين عالي الكثافة) HDPE يحتوي كل منها على 90 قرص مغلف بغشاء رقيق.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الشركة المالكة لحقوق التسويق:</p><p dir="RTL">ميرك شارب آند دوهم المحدودة، 120 مورجيت، لندن، إي سي 2 إم 6 يو آر ، المملكة المتحدة</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">الشركة الصانعة:</p><p dir="RTL">إم إس دي إنترناشيونال جي إم بي إتش تي /إية إم إس دي</p><p dir="RTL">&nbsp;أيرلندا (باليدين)</p><p dir="RTL">&nbsp;كيلشيلان ، كلونيمل ، شركة تيبيراري</p><p dir="RTL">أيرلندا</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة لهذه النشرة في ديسمبر 2023
مراجعة رقم (1)

للإبلاغ عن أي أعراض جانبية:
المملكة العربية السعودية: 
المركز الوطني للتيقظ الدوائي (NPC):
فاكس: 7662-205-11-00966
مركز الاتصال بالهيئة العامة للغذاء والدواء: 19999
البريد الإلكتروني: npc.drug@sfda.gov.sa
الموقع الإلكتروني: https://ade.sfda.gov.sa

دول مجلس التعاون الخليجي الأخرى: 
يرجى الاتصال بالسلطة المختصة ذات الصلة.


إن هذا المستحضر هو دواء
-	الدواء مستحضر يؤثر على صحتك وتناوله خلافًا للتعليمات يعرضك للخطر.
-	اتبع بدقة وصفة الطبيب وطريقة الاستعمال وتعليمات الصيدلى الذى صرفها.
-	الطبيب والصيدلي هما الخبيران في الأدوية وفوائدها ومخاطرها.
-	لا تقطع مدة العلاج المحددة لك بنفسك.
-	لا تكرر العلاج بدون استشارة الطبيب.
-	احفظ جميع الأدوية بعيدًا عن متناول الأطفال.

مجلس وزراء الصحة العرب 
اتحاد الصيادلة العرب
نشرة معلومات المريض هذه معتمدة من قبل الهيئة العامة للغذاء والدواء بالمملكة العربية السعودية

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Welireg™ 40 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 40 mg of belzutifan.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet)
Blue, oval tablet with a length of 13.36 mm and a width of 8.20 mm, “177” on one side. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Welireg is indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for VHL associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumours (pNET), and for whom localised procedures are unsuitable or undesirable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Therapy must be initiated and supervised by specialist physicians experienced in the treatment of cancer.</p><p>&nbsp;</p><p><u>Posology</u></p><p>The recommended dose of Welireg is 120&nbsp;mg (three 40&nbsp;mg tablets) administered orally once daily, with or without food. Tablets should be swallowed whole.</p><p>&nbsp;</p><p>Treatment should continue until disease progression or unacceptable toxicity occurs.</p><p>&nbsp;</p><p><em>Missed dose </em></p><p>If a dose of Welireg is missed, it can be taken as soon as possible on the same day. The regular daily dose should be resumed the next day. Extra tablets should not be taken to make up for the missed dose.</p><p>&nbsp;</p><p>If vomiting occurs any time after taking Welireg, the dose should not be retaken. The next dose should be taken the next day.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Dose Modifications</em></p><p>Dosage modifications for Welireg for adverse reactions are summarised in Table 1 (see section 4.4).</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Table</strong>&nbsp;<strong>1: Recommended Dose Modifications </strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:624px"><thead><tr><td style="vertical-align:top"><p><strong>Adverse Reactions</strong></p></td><td style="vertical-align:top"><p><strong>Severity*</strong></p></td><td style="vertical-align:top"><p><strong>Dose Modification</strong></p></td></tr></thead><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Anaemia</p><p><em>(see section 4.4)</em></p></td><td style="vertical-align:top"><p>Grade&nbsp;3: Haemoglobin (Hgb &lt;&nbsp;8g&nbsp;/dL) transfusion indicated</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold until resolved to &le;&nbsp;Grade&nbsp;2 (Hgb &ge;&nbsp;8&nbsp;g/dL).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Resume at the same or reduced dose (reduce by 40&nbsp;mg) or consider discontinuing depending on the severity and persistence of anaemia.</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;4: Life-threatening or urgent intervention indicated</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold until resolved to &le;&nbsp;Grade&nbsp;2 (Hgb &ge;&nbsp;8&nbsp;g/dL).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Resume at a reduced dose (reduce by 40&nbsp;mg) or permanently discontinue.</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Hypoxia</p><p><em>(see section 4.4)</em></p></td><td style="vertical-align:top"><p>Grade 2: Decreased oxygen saturation with exercise (e.g. pulse oximeter &lt;&nbsp;88%) intermittent supplemental oxygen</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Consider withholding until resolved</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Resume at the same dose or at a reduced dose depending on the severity of hypoxia.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;3: Decreased oxygen saturation at rest (e.g. pulse oximeter &lt;88% or PaO&sup2; &lt;=55 mm Hg)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold until resolved to &le;&nbsp;Grade&nbsp;2</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Resume at reduced dose (reduce by 40&nbsp;mg) or discontinue depending on the severity and persistence of hypoxia.</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;4: Life-threatening</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Permanently discontinue.</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Other Adverse</p><p>Reactions</p><p><em>(see section&nbsp;4.8)</em></p></td><td style="vertical-align:top"><p>Grade 3</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold dosing until resolved to &le;&nbsp;Grade 2.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Consider resuming at a reduced dose (reduce by 40&nbsp;mg).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Permanently discontinue upon recurrence of Grade&nbsp;3.</p></td></tr><tr><td style="vertical-align:top"><p>Grade 4</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Permanently discontinue.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>*Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><u>Special Populations</u></p><p><u>&nbsp;</u></p><p><em>Elderly (&ge;</em>&nbsp;<em>65</em>&nbsp;<em>years old)</em></p><p>No dose adjustment is recommended for elderly patients. There are limited data available on the use of Welireg in patients aged 65&nbsp;years and over (see sections 5.1 and 5.2).<em> </em></p><p><em>&nbsp;</em></p><p><em>Renal impairment</em></p><p>No dose adjustment of Welireg is recommended in patients with mild or moderate renal impairment (eGFR &ge;&nbsp;30&nbsp;mL/minute/1.73&nbsp;m<sup>2</sup>). Welireg has not been studied in patients with severe renal impairment (see section 5.2).</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>No dose adjustment of Welireg is recommended in patients with mild hepatic impairment. Welireg has not been studied in patients with moderate or severe hepatic impairment (see section&nbsp;5.2).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of Welireg in children less than 18 years of age has not yet been established.</p><p>No data are available.</p><p>&nbsp;</p><p><u>Method of administration </u></p><p>Welireg is for oral use.</p><p>It should be swallowed whole and may be taken with or without food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Anaemia due to decreased erythropoietin</u></p><p>WELIREG can cause severe anemia that can require blood transfusion. Monitor for anemia before initiation of, and periodically throughout, treatment with WELIREG. Transfuse patients as clinically indicated. For patients with hemoglobin &lt; 8g/dL, withhold WELIREG until 8g/dL, then resume at the same or reduced dose or permanently discontinue WELIREG, depending on the severity of anemia. For life threatening anemia or when urgent intervention is indicated, withhold WELIREG until hemoglobin 8g/dL, then resume at a reduced dose or permanently discontinue WELIREG.&nbsp; In LITESPARK-004, decreased hemoglobin occurred in 93% of patients and 8.2% had Grade 3 events. Median time to onset of anemia was 30 days (range: 1 day to 8.4 months).</p><p>The safety of erythropoiesis stimulating agents (ESAs) for treatment of anemia in patients with VHL disease treated with WELIREG has not been established. Randomized controlled trials in patients with cancer receiving myelosuppressive chemotherapy with ESAs have shown that ESAs increased the risks of death and serious cardiovascular reactions, and decreased progression-free survival and/or overall survival.</p><p>See the prescribing information for ESAs for more information.</p><p>&nbsp;</p><p><u>Hypoxia</u></p><p>Belzutifan can cause severe hypoxia that may require discontinuation, supplemental oxygen, or</p><p>hospitalisation (see section&nbsp;4.2).</p><p>&nbsp;</p><p>Patients should be monitored for oxygen saturation with pulse oximetry before initiation of and periodically throughout treatment with belzutifan with more frequent monitoring within the first 6&nbsp;months of treatment (see section 5.1). In light of the risk of hypoxia, smoking cessation is recommended.</p><p>&nbsp;</p><p>For Grade&nbsp;2 hypoxia, providing supplemental oxygen and continuing or withholding treatment should be considered. If withheld, belzutifan should be resumed at a reduced dose. For patients who have Grade&nbsp;3 hypoxia, belzutifan should be withheld, hypoxia treated, and dose reduction should be considered. If Grade 3 hypoxia continues to recur, treatment should be discontinued. For Grade&nbsp;4 hypoxia, treatment should be permanently discontinued (see section&nbsp;4.2).</p><p><u>&nbsp;</u></p><p><u>Embryo-foetal toxicity</u></p><p>Based on findings in animals, belzutifan may cause foetal harm, including foetal loss, in humans. In a rat study, belzutifan caused embryo-foetal toxicity when administered during the period of organogenesis at maternal exposures that were lower than the human exposures at the recommended dose of 120&nbsp;mg daily (see section&nbsp;5.3).</p><p>&nbsp;</p><p>Females of reproductive potential should be advised to use highly effective non-hormonal contraceptive methods during treatment with belzutifan and for 1&nbsp;week after the last dose, since belzutifan can render some hormonal contraceptives ineffective (see sections&nbsp;4.5 and 4.6). &nbsp;Advise male patients and their female partners of reproductive potential to use highly effective contraception during treatment with belzutifan and for 1&nbsp;week after the last dose (see section 4.6). Advise male patients with female partners who are pregnant to use a barrier method of contraception during treatment with belzutifan and 1 week after the last dose.</p><p>&nbsp;</p><p><u>Information about some of the ingredients </u></p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dosage unit, that is to say essentially &lsquo;sodium‑free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>In vitro</em> and pharmacogenomic studies indicate that belzutifan is metabolised by UGT2B17 and by CYP2C19.</p><p><u>Effects of </u><u>belzutifan on other medicinal products</u></p><p>&nbsp;</p><p>Coadministration of Welireg with CYP3A4 substrates, including hormonal contraceptives, decreases concentrations of CYP3A substrates (see sections 5.1 and 5.2), which may reduce the efficacy of these substrates. The magnitude of this reduction may be more pronounced in patients who are dual UGT2B17 and CYP2C19 poor metabolisers (see section&nbsp;5.1)<em>.</em></p><p><em>&nbsp;</em></p><p>Avoid coadministration of belzutifan with sensitive CYP3A4 substrates, for which minimal decrease in concentration may lead to therapeutic failures of the substrate. If coadministration cannot be avoided, increase the sensitive CYP3A4 substrate dosage in accordance with its summary of product characteristics.</p><p>&nbsp;</p><p>Coadministration of WELIREG with hormonal contraceptives may lead to contraceptive failure or an increase in breakthrough bleeding.</p><p>&nbsp;</p><p><u>Effects of other medicinal products on belzutifan</u></p><p>Co-administration of belzutifan with inhibitors of UGT2B17 or CYP2C19 increases plasma exposures of belzutifan, which may increase the incidence and severity of adverse reactions of&nbsp;belzutifan. Monitor for anaemia and hypoxia and reduce the dosage of&nbsp;belzutifan&nbsp;as recommended.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no data from the use of belzutifan in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Belzutifan is not recommended during pregnancy and in women of childbearing potential not using contraception.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>It is unknown whether belzutifan or its metabolites are excreted in human milk. A risk to newborns/infants cannot be excluded. Breast-feeding should be discontinued during treatment with belzutifan and for 1&nbsp;week after the last dose.</p><p><u>&nbsp;</u></p><p><u>Women of child-bearing potential/ contraception in males and females</u></p><p><em>Pregnancy Testing</em></p><p>The pregnancy status of females of reproductive potential should be verified prior to initiating treatment with belzutifan.</p><p>&nbsp;</p><p><em>Contraception</em></p><p>Belzutifan may cause embryo‑foetal harm, including foetal loss, when administered to a pregnant woman (see sections 4.4 and 5.3).</p><p>&nbsp;</p><p><em>Females</em></p><p>Females of reproductive potential should be advised to use highly effective contraception during treatment with belzutifan and for at least 1&nbsp;week after the last dose. Use of belzutifan may reduce the efficacy of hormonal contraceptives. Patients using hormonal contraceptives should be advised to use an alternative non‑hormonal contraceptive method or have their male partner use a condom during treatment with belzutifan (see section 4.4).</p><p>&nbsp;</p><p><em>Males</em></p><p>Male patients and their female partner of reproductive potential should be advised to use highly effective contraception during male patient treatment with belzutifan and for at least 1&nbsp;week after the last dose (see section 4.4). Advise male patients with female partners who are pregnant to use barrier method of contraception during treatment with belzutifan and 1 week after the last dose.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Based on findings in animals, belzutifan may impair fertility in males and females of reproductive potential (see section 5.3). Advise patients of this potential risk. The reversibility of the effect on fertility is unknown. Family planning should be discussed with patients as appropriate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Belzutifan may have a minor influence on the ability to drive and use machines. Dizziness and fatigue may occur following administration of belzutifan (see section 4.8).</p><p>&nbsp;</p><p>Patients should be advised not to drive and use machines, until they are reasonably certain belzutifan therapy does not affect them adversely.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The safety of belzutifan was evaluated in an open‑label Phase 2 clinical study (LITESPARK-004), in 61&nbsp;patients with VHL disease‑associated RCC and who did not require immediate nephrectomy or partial nephrectomy. Patients were treated with 120&nbsp;mg belzutifan once daily. The median duration of exposure to belzutifan was 28.9 months (range: 1.9 to 37.5).</p><p>&nbsp;</p><p>The most common adverse reactions with belzutifan were anaemia (90%), fatigue (71%), dizziness (44%) and nausea (36%).</p><p>&nbsp;</p><p>The most common Grade&nbsp;3 or 4 adverse reactions were anaemia (10%), and fatigue (5%).</p><p>&nbsp;</p><p>Serious adverse reactions occurred in 5% of patients who received belzutifan, including anaemia, dyspnoea and hypoxia (1 patient each).</p><p>&nbsp;</p><p>Dose interruption of belzutifan due to adverse reactions occurred in about 23% of patients. The most common adverse reactions resulting in dose interruption of belzutifan were fatigue (13.1%), nausea (8.2%), and anaemia (4.9%).</p><p>Dose reduction of belzutifan due to adverse reactions occurred in about 11.5% of patients. The adverse reactions resulting in dose reduction of belzutifan were fatigue (8.2%), anaemia, and hypoxia (one patient each 1.6%).</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions.</u></p><p>Adverse reactions reported in clinical studies of belzutifan are listed in the table below by MedDRA system organ class and by frequency. Frequencies are defined as very common (&ge;&nbsp;1/10), common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10), uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100), rare (&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1,000), and very rare (&lt;&nbsp;1/10,000).</p><p>&nbsp;</p><p><strong>Table&nbsp;2: Adverse drug reactions for Welireg 120&nbsp;mg Once Daily</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Adverse Drug Reaction</strong></p></td><td style="vertical-align:top"><p><strong>All Grades</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3 &ndash; 4</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Anaemia</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Dyspnoea</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypoxia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Weight Increased</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr></tbody></table><p>The safety of belzutifan was also evaluated in a Phase 1 clinical study (Study‑001), in 58&nbsp;patients with non-VHL disease‑associated advanced solid tumours, treated with belzutifan 120&nbsp;mg once daily. Study‑001 patients differed from VHL‑associated RCC patients (LITESPARK-004). Study‑001 patients were older (median: 62.5 years old; range: 39 to 75 vs. 41.0; range: 19 to 66), had worse ECOG PS (scale 1: 63.8% in study-001 vs. 16.4% in LITESPARK-004), had metastatic disease, had prior systemic therapies, had more comorbidities, and had lower baseline haemoglobin levels at treatment initiation (median: 119; range: 89 to 173 vs. 140; range 91 to 171). Study‑001 had a median duration of exposure to belzutifan of 25.4&nbsp;weeks (range: 1.1 to 145.9&nbsp;weeks). The adverse reactions with belzutifan in Study‑001 were anaemia (76%), fatigue (71%), dyspnoea (47%), nausea (35%), hypoxia (29%), dizziness (22%) and weight increased (10%). The adverse reactions resulting in dose interruption of belzutifan were hypoxia (10.3%), anaemia (8.6%), dyspnoea (5.2%), fatigue (1.7%) and nausea (1.7%). The adverse reactions resulting in dose reduction of belzutifan were hypoxia (3.4%), nausea (1.7%) and fatigue (1.7%). The adverse reactions resulting in discontinuation were hypoxia (3.4%) and fatigue (1.7%).</p><p><u>&nbsp;</u></p><p><u>Description of selected adverse reactions</u></p><p><u>&nbsp;</u></p><p><u>Anaemia due to decreased erythropoietin (see section 5.1)</u></p><p>In LITESPARK-004 anaemia was reported in 90.2% of all patients with Grade&nbsp;3 anaemia occurring in 9.8%. Median time to onset of all Grade anaemia events was 30&nbsp;days (range: 1 day to 8.4&nbsp;months). Most of the anaemia occurred in the first 3&nbsp;months of treatment initiation and was not progressive. Three (4.9%) participants had anaemia events leading to study drug interruption and 1&nbsp;participant (1.6%) had a dose reduction due to anaemia. No participant discontinued treatment due to anaemia. Of the 13&nbsp;patients that were treated with an ESA, 4 received treatment with both an ESA and blood transfusions, while 9 received treatment with an ESA alone. Patients received an ESA based on haemoglobin levels and physician discretion Anaemia was reported as resolved in 13 (21.3%) of participants and resolving or not yet resolved in 40 (65.6%) participants.</p><p>&nbsp;</p><p>In another clinical study (Study‑001) for the treatment of non‑VHL disease-associated advanced solid tumours using the same dose of belzutifan, anaemia was reported in 44&nbsp;patients (75.9%) with Grade 3 anaemia occurring in 16&nbsp;patients (27.6%).</p><p><u>&nbsp;</u></p><p><u>Hypoxia (see section 5.2)</u></p><p>In LITESPARK-004 Grade 3 hypoxia occurred in 1&nbsp;patient (1.6%). This case of hypoxia occurred within 2&nbsp;months of treatment initiation in a patient with previously undiagnosed restrictive lung disease and was asymptomatic. This patient did not receive supplemental oxygen and was managed with dose reduction to 80&nbsp;mg once daily with no recurrence of hypoxia. In another clinical study (Study-001) for the treatment of non‑VHL disease-associated advanced solid tumours using the same dose of belzutifan, hypoxia occurred in 17&nbsp;patients (29.3%), with Grade 3 hypoxia occurring in 9&nbsp;patients (15.5%).</p><p><u>&nbsp;</u></p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Saudi Arabia: </u></p><p>The National Pharmacovigilance Centre (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Other GCC States: </u></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no specific treatment for belzutifan overdose. In cases of suspected overdose, withhold belzutifan and institute supportive care. The highest dose of belzutifan studied clinically was 240&nbsp;mg daily (120&nbsp;mg twice a day or 240&nbsp;mg once a day). Adverse reactions observed in patients receiving more than 120&nbsp;mg once a day were generally similar to those observed at other doses except for Grade&nbsp;3 hypoxia observed at 120&nbsp;mg twice a day and Grade&nbsp;4 thrombocytopenia observed at 240&nbsp;mg once daily.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: other antineoplastic agents, ATC code: L01XX74 belzutifan</p><p><strong>&nbsp;</strong></p><p><u>Mechanism of action</u></p><p>Belzutifan is an inhibitor of hypoxia-inducible factor 2&nbsp;alpha (HIF-2&alpha;). HIF-2&alpha; is a transcription factor that plays a role in oxygen sensing by regulating genes that promote adaptation to hypoxia. Under normal oxygen levels, HIF-2&alpha; is targeted for ubiquitin-proteasomal degradation by VHL protein. Lack of functional VHL protein results in stabilization and accumulation of HIF-2&alpha;. Upon stabilization, HIF-2&alpha; translocates into the nucleus and interacts with hypoxia-inducible factor 1&nbsp;beta (HIF-1b) to form a transcriptional complex that regulates expression of downstream genes, including genes associated with cellular proliferation, angiogenesis, and tumour growth (including CCND1, VEGFA, SLC2A1 (GLUT1), IGFBP3, TGFa, AXL, CXCR4, IL6). Belzutifan binds to HIF-2&alpha;, and in conditions of hypoxia or impairment of VHL protein function, belzutifan blocks the HIF-2&alpha;-HIF-1b interaction, leading to reduced transcription and expression of HIF-2&alpha; target genes. <em>In vivo</em>, belzutifan demonstrated anti-tumour activity in mouse xenograft models of renal cell carcinoma.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>LITESPARK-004 Circulating plasma levels of EPO were monitored in patients as a pharmacodynamic marker of HIF‑2&alpha; inhibition. Reductions in EPO were observed to be dose/exposure dependent and showed a plateauing effect on reduction at exposures achieved with doses above 120&nbsp;mg once daily. The maximum EPO suppression occurred following 2 weeks of consecutive dosing of WELIREG (mean percent decrease from baseline of approximately 60%). Mean EPO levels gradually returned to baseline values after 12&nbsp;weeks of treatment.</p><p><em>&nbsp;</em></p><p><u>Pharmacogenomics</u></p><p>Belzutifan is primarily metabolised by UGT2B17 and CYP2C19. The activity of these enzymes varies among individuals who carry different genetic variants, which may impact belzutifan concentrations. Poor metabolisers are individuals who are considered to have no enzyme activity. Approximately 15% of Caucasians, 11% of Latinos, 6% of African Americans, 38% of South Asians, and 70% of East Asians are UGT2B17 poor metabolisers. Approximately 2% of Caucasians, 1% of Latinos, 5% of African Americans, 8% of South Asians, and 13% of East Asians are CYP2C19 poor metabolisers. Approximately 0.3% of Caucasians, 0.1% of Latinos, 0.3% of African Americans, 3% of South Asians, and 9% of East Asians are dual UGT2B17 and CYP2C19 poor metabolisers.&nbsp;</p><p>&nbsp;</p><p>The impact of CYP2C19 and UGT2B17 poor metabolisers on belzutifan exposure was assessed in a population PK analysis. Based on the analysis, VHL disease-associated RCC patients who are UGT2B17, CYP2C19, or dual UGT2B17 and CYP2C19 poor metabolisers, are projected to have 1.5‑, 1.6‑ or 2.3‑fold the exposures (steady‑state AUC<sub>0-24</sub>), respectively, compared to a typical reference patient (UGT2B17 intermediate metaboliser, CYP2C19 non-poor metaboliser) for the recommended dose. No dose adjustment is recommended based on exposure‑response analyses for efficacy and safety and the risk‑benefit profile.</p><p>&nbsp;</p><p><u>Clinical efficacy </u></p><p>The efficacy of belzutifan was investigated in LITESPARK-004 , an open‑label Phase 2 clinical study in 61&nbsp;patients with confirmed VHL disease, based on a VHL germline alteration, who had at least one measurable solid tumour (as defined by RECIST v1.1) localised to the kidney and who did not require immediate surgery. Enrolled patients had other VHL-associated tumours including CNS haemangioblastomas and pNET, identified by radiological appearance. The study excluded patients who had any evidence of metastatic disease, either RCC or other VHL disease‑associated tumours. Other exclusion criteria were immediate need for surgical intervention for tumour treatment, any major surgical procedure completed within 4&nbsp;weeks prior to study enrolment, any major cardiovascular event within 6&nbsp;months prior to study drug administration, or prior systemic treatments for VHL disease‑associated RCC. Patients were monitored for anaemia and hypoxia before initiation of belzutifan, and then every 2 weeks for the first month, monthly for the next 5 months, and then every 3 months thereafter throughout treatment.</p><p>&nbsp;</p><p>The study population characteristics were: median age of 41&nbsp;years [range 19-66 years], 3.3% age 65 or older; 52.5% male; 90.2% White; and 82.0% had an ECOG PS of 0 and 16.4% had an ECOG PS of 1. Seventy-seven percent of patients had prior RCC surgical procedures encompassing ablative procedures, partial nephrectomy, radical nephrectomy.</p><p>The median diameter of RCC target lesions per central independent review committee (IRC) was&nbsp;2.2 cm&nbsp;(range&nbsp;1-6.1). Median time from initial radiographic diagnosis of VHL‑associated RCC tumours that led to enrolment on Study&nbsp;004 to the time of treatment with WELIREG was 17.9&nbsp;months (range&nbsp;2.8‑96.7).</p><p>&nbsp;</p><p>Patients received belzutifan at a dose of 120&nbsp;mg once daily. Patients were evaluated radiologically approximately 12&nbsp;weeks after initiation of treatment and every 12&nbsp;weeks thereafter. Treatment was continued until progression of disease or unacceptable toxicity. The effect of intermittent use and long treatment interruptions of belzutifan have not been evaluated.</p><p>&nbsp;</p><p>The primary efficacy endpoint for the treatment of VHL disease‑associated RCC was objective response rate (ORR) measured by radiology assessment using RECIST v1.1 as assessed by IRC. Secondary efficacy endpoints included duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), time to response (TTR), and time to surgery (TTS).</p><p>Table&nbsp;3 summarises the efficacy results for VHL disease‑associated RCC tumours in LITESPARK-004 at a median follow-up time of 29.2 months (range 4.2-37.5). The median duration of exposure was 28.9&nbsp;months (range 1.9-37.5).</p><p>&nbsp;</p><p><strong>Table</strong>&nbsp;<strong>3: Efficacy results in VHL disease‑associated RCC tumours in LITESPARK-004 </strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:462px"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>Belzutifan</strong></p><p><strong>120&nbsp;mg daily</strong></p><p><strong>n=61</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Objective response rate</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>ORR* (95% CI)</p></td><td style="vertical-align:top"><p>59.0% (45.7, 71.4)</p></td></tr><tr><td style="vertical-align:top"><p>Complete response</p></td><td style="vertical-align:top"><p>3.3%</p></td></tr><tr><td style="vertical-align:top"><p>Partial response</p></td><td style="vertical-align:top"><p>55.7%</p></td></tr><tr><td style="vertical-align:top"><p>Stable disease</p></td><td style="vertical-align:top"><p>39.3%</p></td></tr><tr><td style="vertical-align:top"><p>Disease control rate<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>98.4%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Response duration</strong><strong><sup>&Dagger;</sup></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median in weeks (range)</p></td><td style="vertical-align:top"><p>Not reached</p><p>(36.1+, 119.9+)</p></td></tr><tr><td style="vertical-align:top"><p>% (n) with duration &ge;&nbsp;18&nbsp;months</p></td><td style="vertical-align:top"><p>95.0% (19)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Time to response</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median in weeks (range)</p></td><td style="vertical-align:top"><p>&nbsp;47.6 (11.6, 96.6)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Time to surgery</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median in weeks (95% CI)</p></td><td style="vertical-align:top"><p>Not reached</p><p>(NE, NE)</p></td></tr><tr><td style="vertical-align:top"><p><strong>PFS</strong><strong><sup>&Dagger;</sup></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median in weeks (95% CI)</p></td><td style="vertical-align:top"><p>Median not estimated<sup>&sect;</sup></p></td></tr><tr><td style="vertical-align:top"><p>24-month PFS rate</p></td><td style="vertical-align:top"><p>94.6%</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>*&nbsp; Response: Best objective response as confirmed complete response or partial response</p><p><sup>&dagger;</sup>&nbsp;&nbsp; Based on best response of stable disease or better</p><p><sup>&Dagger;</sup>&nbsp;&nbsp; Based on Kaplan-Meier estimates</p><p>+&nbsp; Denotes ongoing response</p><p>&nbsp;</p><p><sup>&sect;&nbsp;&nbsp;&nbsp; </sup>Reliable median could not be estimated<sup> </sup>due to the number of progression events (n=7) and a progression event that occurred at the latest timepoint when only 1 patient was at risk.</p><p>NE = Not estimable</p><p>Data cut-off: July 15, 2021</p><p>&nbsp;</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>During this period of treatment, two out of 61 (3.3%) patients required an RCC tumour reduction procedure. For comparison, in one retrospective natural history study of VHL patients with RCC, 28.7% of patients had their first tumour reduction procedure within 24 months of follow-up.</p><p>&nbsp;</p><p>Objective response rates were in other VHL diseases associated tumours: 38% CNS haemangioblastomas (95% CI: 24.7, 52.8; 19 out of 50 patients), and 90% for pancreatic neuroendocrine tumours (95% CI: 68.3, 98.8; 18 out of 20 patients).</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The Medicines and Healthcare products Regulatory Agency (MHRA)&nbsp;has waived the obligation to submit the results of studies with belzutifan in all subsets of the paediatric population in renal neoplasms (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of belzutifan are similar in healthy subjects and patients with solid tumours including advanced RCC. Based on a population‑PK model analysis, the steady-state geometric mean (GCV%) for C<sub>max</sub> and AUC<sub>0-24hr</sub> for 120&nbsp;mg once daily in patients with VHL disease‑associated RCC are predicted to be 1.4&nbsp;&mu;g/mL (39.8%) and 16.7&nbsp;&micro;g&bull;hr/mL (52.3%), respectively. Steady‑state is reached after approximately 3&nbsp;days of once daily dosing with belzutifan.</p><p><strong>&nbsp;</strong></p><p><u>Absorption</u></p><p>Following single-dose oral administration of 120&nbsp;mg of belzutifan, peak plasma concentrations (median T<sub>max</sub>) of belzutifan occurred at 1.5&nbsp;hours post dose.</p><p><strong>&nbsp;</strong></p><p><em>Effect of food</em></p><p>A high-fat, high-calorie meal delayed peak belzutifan concentration by approximately 2&nbsp;hours, but had no effect on exposure (AUC). There was a modest decrease of C<sub>max</sub> by 35% following consumption of a high-fat, high-calorie meal, but this was not clinically meaningful. Therefore, belzutifan can be taken without regard to food.</p><p><strong>&nbsp;</strong></p><p><u>&nbsp;</u></p><p><u>Distribution</u></p><p>The mean steady‑state apparent volume of distribution of belzutifan following an oral dose is 130&nbsp;L. Plasma protein binding of belzutifan is 45%. The blood-to-plasma concentration ratio of belzutifan is 0.88.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>The mean apparent clearance of belzutifan is 7.3&nbsp;L/hr and the mean elimination half-life is 14&nbsp;hrs.</p><p>&nbsp;</p><p><u>Metabolism</u></p><p>Belzutifan is primarily metabolised by UGT2B17 and CYP2C19 and to a lesser extent by CYP3A4. Both UGT2B17 and CYP2C19 display genetic polymorphisms (see section 5.1).</p><p>&nbsp;</p><p><u>Linearity</u></p><p>The plasma C<sub>max</sub> and AUC increased in a dose‑proportional manner following doses up to the recommended dose for belzutifan.</p><p>&nbsp;</p><p><u>Special Populations</u></p><p><em><u>&nbsp;</u></em></p><p><em>Renal impairment</em></p><p>No relevant increase in exposure (AUC) was observed for subjects with mild or moderate renal impairment. Renal impairment (as evaluated by eGFR) was not identified as a significant covariate in the population pharmacokinetic analysis. The pharmacokinetics of belzutifan have not been studied in patients with severe renal impairment<em> </em>(see sections 4.2 and 5.2).</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>No relevant increase in exposure (AUC) was observed for subjects with mild hepatic impairment (using NCI index) based on population pharmacokinetic analysis. The pharmacokinetics of belzutifan have not been studied in patients with moderate or severe hepatic impairment<em> </em>(see sections 4.2 and 5.2).</p><p>&nbsp;</p><p><em>Dual UGT2BI7 and CYP2C19 Poor Metabolisers</em></p><p>Patients who are dual UGT2B17 and CYP2C19 poor metabolisers have higher&nbsp;belzutifan&nbsp;exposures, which may increase the incidence and severity of adverse reactions of&nbsp;belzutifan and should be closely monitored (see sections 4.4, 4.8 and 5.1).</p><p>&nbsp;</p><p><em>Effects of Age, Gender, Ethnicity, Race, and Body Weight</em></p><p>Based on a population pharmacokinetic analysis, age, gender, ethnicity, race, and body weight do not have a clinically meaningful effect on the pharmacokinetics of belzutifan. Potential differences in exposure across races are possible due to different frequencies of metabolising enzymes (see section&nbsp;5.1).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>No studies with belzutifan have been performed in paediatric patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Carcinogenicity</u></p><p>Carcinogenicity studies have not been conducted with belzutifan.</p><p><u>&nbsp;</u></p><p><u>Genotoxicity</u></p><p>Belzutifan was not genotoxic in <em>in vitro</em> bacterial mutagenesis and<em> </em>micronucleus assays, and an <em>in vivo</em> rat micronucleus assay.</p><p>&nbsp;</p><p><u>Reproductive toxicity</u></p><p>Fertility studies with belzutifan have not been conducted. In the 3‑month repeat‑dose toxicity study in rats, irreversible testicular atrophy/degeneration was observed at exposures lower than the human exposure at the recommended dose of 120&nbsp;mg daily. There were no findings in female reproductive organs in either rat or dog 3‑month toxicity studies.</p><p>&nbsp;</p><p><u>Development</u></p><p>In a rat embryo‑foetal development study, administration of belzutifan during organogenesis caused embryo‑foetal lethality up to 100%, reduced foetal body weight, and foetal skeletal abnormalities at exposures similar to or below the human exposure at the recommended dose of 120&nbsp;mg daily. Based on the observed embryo‑foetal lethality in rats treated with belzutifan, a pre‑ and postnatal developmental toxicity study was not conducted.</p><p>&nbsp;</p><p><u>Acute toxicity</u></p><p>No formal acute toxicity studies have been conducted. However, the toxicity after a single‑dose was assessed from the repeat‑dose oral toxicity studies in rats (from 2 to 200&nbsp;mg/kg/day) and dogs (from 1 to 30&nbsp;mg/kg/day). No acute toxicities were observed in these studies</p><p>&nbsp;</p><p><u>Chronic toxicology</u></p><p>Repeat‑dose oral toxicity studies were conducted in rats and dogs for up to 3&nbsp;months duration. Reversible decreases in red blood cell parameters were observed in rats and dogs at exposures lower than the human exposure at the recommended dose of 120&nbsp;mg daily. Belzutifan caused irreversible testicular atrophy/degeneration and oligospermia in rats at exposures lower than the human exposure at the recommended dose of 120&nbsp;mg daily. No testicular toxicity was observed in dogs up to an exposure similar to the human exposure at the recommended dose of 120&nbsp;mg daily.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Core tablet</em></strong></p><p>Hypromellose Acetate Succinate</p><p>Cellulose Microcrystalline</p><p>Mannitol</p><p>Crosscarmellose Sodium</p><p>Silica, Colloidal Anhydrous</p><p>Magnesium Stearate</p><p>&nbsp;</p><p><strong><em>Film-coating</em></strong></p><p>Polyvinyl Alcohol</p><p>Titanium Dioxide</p><p>Macrogol</p><p>Talc</p><p>Indigo Carmine Aluminium Lake</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Each carton contains a high density polyethylene (HDPE) bottle with a polypropylene child‑resistant closure with silica gel desiccant. Each bottle contains 90&nbsp;film‑coated tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorization Holder:
Merck Sharp & Dohme (UK) Limited
120 Moorgate
London 
EC2M 6UR 
United Kingdom

Manufacturer:
MSD International GmbH T/A MSD
Ireland (Ballydine)
Kilsheelan, Clonmel, Co. Tipperary,
Ireland
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                08 January 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>